New Happenings, developments and much more.
Check back regularly or send us a message to update you on new posts.
Posted 19th November 2025
Posted 31st August 2025
Posted 3 months ago
By NHP Office
20250831 RCPath National Examiner's Good Practice in Sickle Cell Disease
The guidance provides good practice advice for medical examiners on recognising the impact of SCD in various contexts including deaths and coroner referrals.
Posted 21st November 2024
Posted 1 year ago
By NHP Office
NHP 2023/2024 Annual Report
The NHP activity report for 2023/2024 (published 21 November 2024) gives an overview of its core and partner-related activities.
Posted 19th November 2024
Posted 1 year ago
By NHP Office
New NHP Chair Announced – Dr Kate Gardner
Following the stepping down of Professor Baba Inusa, Dr Kate Gardner has been appointed the new NHP Chair.
Posted 10th October 2024
Posted 1 year ago
By NHP Office
Voxelotor (Oxbryta®) Withdrawal - NHP Patient Letter
Following the unforeseen Pfizer withdrawal of Voxelotor (Oxbryta®) Medication for Sickle Cell Disease on 25th September 2024, the NHP provided a letter assist affected Sickle Cell Disorder patients.
Posted 25th September 2024
Posted 1 year ago
By NHP Office
Pfizer Withdraws OXBRYTA ® (Voxelotor) for the treatment of sickle cell disease (SCD)
On 25th September 2024, Pfizer announced its voluntarily withdrawing of all lots of OXBRYTA ® (Voxelotor) for the treatment of sickle cell disease (SCD).
Posted 8th August 2024
Posted 1 year ago
By NHP Office
Gene-editing therapy, Casgevy, for Transfusion Dependent Thalassaemia
On 08.08.2024 the National Institute for Health and Care Excellence (NICE) approves NHS use of Casgevy ™ [Exagamglogene Autotemcel (‘Exa-Cel’)] for treatment of Transfusion-dependent beta Thalassaemia
Posted 1st April 2024
Posted 2 years ago
By NHP Office
A Chapter Closes: Professor Baba Inusa Leaves the National Haemoglobinopathy Panel (NHP)
The Founding Chair of the NHP, Professor Baba Inusa, announces his departure from the NHS and his NHP Role in March 2024.
